Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.59 |
| ▸ | HTR2C | P28335 | 13/20 | 0.56 |
| ▸ | HTR2B | P41595 | 5/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623093 | 0.87 | HTR2C (0.53) | HTR2AHTR2CHTR2BPDE4APDE4B | |
| SCHEMBL1623212 | 0.86 | HTR2A (0.60) | HTR2AHTR2CHTR2BKDM4EHPGD | |
| SCHEMBL1622748 | 0.76 | HTR2A (0.82) | HTR2AHTR2CHTR2BKDM4EHPGD | |
| SCHEMBL1620536 | 0.74 | HTR2A (0.72) | HTR2AHTR2CHTR2B | |
| SCHEMBL1623082 | 0.73 | HTR2A (0.56) | HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL1628359 | 0.73 | HTR2A (0.77) | HTR2AHTR2CHTR2BPDE4APDE4B | |
| SCHEMBL1620638 | 0.73 | HTR2C (0.74) | HTR2AHTR2CHTR2BPDE4APDE4B | |
| SCHEMBL12719536 | 0.71 | HTR2A (0.73) | HTR2AHTR2CHTR2BKDM4EHPGD | |
| SCHEMBL11284926 | 0.69 | HTR2A (0.67) | HTR2AHTR2CPDE4APDE4BPDE4C | |
| SCHEMBL12719554 | 0.68 | HTR2C (0.51) | HTR2AHTR2CHTR2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928099-B2 | Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928099-B2 | Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928099-B2 | Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | ANDREWS MARK | 2010-05-06 | — | — | US | disclosed |
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | ANDREWS MARK | 2010-05-06 | — | — | US | disclosed |
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | ANDREWS MARK | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | HTR2C, HTR2A, HTR5A | HTR2A 2/4885HTR2C 1/4885HTR2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.